Search for New Genetic Causes of Hypercalcemia by Massively Parallel Sequencing of a Genes Panel

Hypercalcemia Clinical Trial

— HyCaGene  

Official title:

Search for New Genetic Causes of Hypercalcemia by Massively Parallel Sequencing of a Genes Panel

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02908542
• Other study ID #: 16-048
• Status: Completed
• Start date: December 2015
• Est. completion date: December 2018

Study information

• Verified date: September 2016
• Source: University Hospital, Caen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hypercalcemia, whether chronic or acute, exposes the patient to potentially serious complications (arrhythmias, nephrolithiasis, nephrocalcinosis, ...). Prevention relies primarily on effective etiological necessary for taking matched load. Under the French reference center for rare disorders of calcium and phosphorus, the investigators looked for mutations in the coding sequence of the CYP24A1 gene (encoding the enzyme responsible for the breakdown of vitamin D), among patients with hypercalcemia without hyperparathyroidism with hypersensitivity to vitamin D. However, only 25% of these patients have a genetic anomaly suggesting the involvement of other genes (Molin et al. 2015). Recently our team, combined with Kaufmann et al. (2014 JCEM) validated the interest of the determination of metabolites of vitamin D by liquid chromatography-tandem mass spectrometry (LC-MS / MS), as biological pre-screening stage for patients with hypercalcemia.

The objective of this project is to complement the molecular and biochemical studies of patients without mutation of the coding sequence of CYP24A1, in a gene candidate approach using massively parallel sequencing (MPS) which allows to study a panel of gene potentially involved in disorder of metabolism of calcium and phosphorus. Highlighted variations will be tested in silico, and if possible in vitro. The investigators will also use LC-MS / MS to evaluate in vivo the effects of these variations on the metabolism of vitamin D, to develop a genotype / phenotype correlation.

The work carried out within the Genetics Department Caen University Hospital in collaboration with physicians of the rare disease reference center of the metabolism of calcium and phosphorus should identify new genetic mechanisms underlying hypercalcemia. At the time of development of personalized medicine, it will adapt the therapy in patients at risk for metabolic complications and / or kidney following administration of vitamin D and finally to offer genetic counseling.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 185
• Est. completion date: December 2018
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion criteria

• Chronic hypercalcemia or at least one episode of acute hypercalcemia not linked to hyperparathyroidism

• Consent to the realization of a genetic analysis for medical purposes Non-inclusion criteria

• Another genetic disorder identified with hypercalcemia (eg Williams-Beuren syndrome)

• Primary hyperparathyroidism (high PTH)

• neoplasia

• granulomatosis

Related Conditions & MeSH terms

• Hypercalcemia

Intervention

Genetic:
• genetic analysis with massively parallel sequencing

Locations

Country	Name	City	State
France	Caen Hospital University	Caen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of identified genetic variations presumed pathogenic		3 years